ChemR23 Program

CCX832 targets the chemo-attractant receptor known as ChemR23. This molecule has been designed to block the pro-inflammatory effects of chemerin, the ligand for ChemR23. Elevated chemerin levels are seen in multiple inflammatory skin diseases, including cutaneous lupus, oral lichen planus and psoriasis. In preclinical studies to date, CCX832 has demonstrated the ability to successfully block ChemR23 and to interrupt the early steps associated with the development of skin inflammation.

CCX832 has completed a Phase I clinical trial in 40 healthy subjects and, subject to further discussion with GSK, we expect to advance this drug candidate into a Phase II proof-of-concept clinical trial for the treatment of skin inflammation. If this clinical trial is successfully completed, GSK may exercise its option to further develop and commercialize CCX832 under our collaboration agreement.